CFTR modulator prior authorization (Kalydeco, Trikafta, Symdeko, Orkambi)
Customize your policy alerts
Sign up for all mediviewcurative policy alerts
Know when mediviewcurative releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization clinical criteria, documentation, and approval durations for CFTR modulator drugs (Kalydeco, Trikafta, Symdeko, Orkambi) for members of Curative Health Plan. Applies to prescribers requesting coverage for these FDA‑approved CFTR modulator indications.
No material clinical or coverage changes in this revision.
Coverage Criteria for CFTR Modulators
Initial Therapy
Initial Approval — Covered when ALL of the following are met for the requested agent:
Applies to all listed agents; document in chart notes within past 6 months
Documented in chart notes within past 6 months
Attestation documented in chart notes
Documented in chart notes within past 6 months
Continuation Therapy
Continuation (Renewal) Approval — Covered when ALL of the following are met:
Documented since baseline
One of: no evidence of elevated LFTs OR hepatology follow-up documenting benefit outweighs risk
Requests for CFTR modulators will not be approved for members with severe hepatic impairment (Child‑Pugh Class C) unless specific follow‑up conditions are met. The plan excludes patients with Child‑Pugh Class C from eligibility for approval. Exception to this exclusion may be considered only when the member is being followed by a hepatologist and the hepatology documentation clearly states that the benefit outweighs the risk of continuing therapy.
The requested CFTR modulator must not be used in combination with another CFTR modulator for the same indication. Concurrent use of more than one CFTR modulator for the same condition is prohibited and will not meet criteria for approval; providers must attest that the patient will NOT be using the requested agent in combination with another CFTR modulator for the requested indication.
Testing, Age, and Lab Timing Requirements
Prior Authorization, Documentation, and Denial Conditions
Prior authorization required; approval conditional on FDA indication and specified documentation
Prior authorization is required for CFTR modulators and will be approved only when the requested medication is being used for an FDA‑approved indication and all applicable initial or continuation criteria are met (genetic confirmation or mutation responsiveness, age within FDA labeling, specialist prescriber/consult, LFT documentation, not used with another CFTR modulator).
- Applies to Kalydeco, Symdeko, Orkambi, Trikafta per their respective criteria and approval durations.
- Initial Trikafta requires LFTs within 1 month prior to start; continued therapy requires LFTs within 365 days.
Concurrent CFTR modulators for same indication not permitted
The plan prohibits concurrent use of more than one CFTR modulator for the same indication; requests where the patient will use the requested agent in combination with another CFTR modulator will not meet criteria for approval.
- Applies to initial and continuation approvals for all listed agents (explicitly stated in initial and continued criteria).
Required documentation: recent genetic test, LFTs, specialist involvement, and Orkambi attestation when requested
Provide chart documentation within the past 6 months confirming genetic testing/mutation status and required lab results; include specialist involvement and any attestation when applicable.
- Chart notes within past 6 months documenting genetic testing showing homozygous F508del or a mutation responsive to the requested drug (or at least one responsive variant for Trikafta).
- Documentation of LFT results (ALT, AST, alkaline phosphatase, bilirubin): within 1 month prior to starting Trikafta (initial) and within 365 days for continued therapy.
- If Orkambi requested, include prescriber attestation that benefits outweigh risks (e.g., respiratory effects, CYP3A interactions).
- Prescriber must be a specialist or have consulted a specialist (e.g., cystic fibrosis specialist or pulmonologist).
Denial triggers: non‑FDA indication, missing criteria or documentation
Requests will be denied if the medication is not being used for an FDA‑approved indication or if required criteria or documentation are missing.
- Missing genetic confirmation of CFTR mutation status (homozygous F508del or mutation responsive) in chart notes within the past 6 months.
- Patient age outside FDA labeling for the requested agent.
- Concurrent use of the requested agent with another CFTR modulator for the same indication.
- Missing required LFT documentation or lack of specialist prescriber/consultation.
- For patients with severe hepatic impairment (Child‑Pugh Class C) without hepatology follow‑up documenting benefit outweighs risk, approval is excluded.
Clinical Background
Cystic fibrosis (CF) is a genetic disorder caused by pathogenic variants in the CFTR gene that impair chloride transport and lead to multi‑system disease. CFTR modulators are targeted therapies designed to correct the underlying CFTR protein defect. Examples included in this policy are ivacaftor (Kalydeco), combination corrector–potentiator products such as lumacaftor/ivacaftor (Orkambi) and tezacaftor/ivacaftor (Symdeko), and the triple‑combination elexacaftor/tezacaftor/ivacaftor (Trikafta). These agents require genetic confirmation that the member’s CFTR variant is responsive to the requested drug, and treatment decisions (including age eligibility and monitoring) follow the FDA‑approved indications referenced in the coverage criteria.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.